



Vyvgart

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0015	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	19/12/2023		SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



X/0003	Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration	14/09/2023	15/11/2023	SmPC, Labelling and PL	
IA/0012	B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier	06/10/2023	n/a		
II/0006	Update of sections 4.4 and 4.5 of the SmPC in order to amend an existing warning on use of vaccination and update drug-drug interaction information on vaccines based on final results from study ARGX-113-2102; this is a phase 1, randomized, open-label, placebo-controlled, parallel-group study to evaluate the immune response to PNEUMOVAX 23 in healthy participants receiving efgartigimod IV 10 mg/kg or placebo. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 2.1 was adopted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	28/09/2023		SmPC and PL	Sections 4.4 and 4.5 of the SmPC are updated to inform that the safety of immunisation with live or live attenuated vaccines and the response to immunisation with these vaccines during treatment with efgartigimod alfa are unknown. For patients that are being treated with efgartigimod alfa, vaccination with live or live attenuated vaccines is generally not recommended. If vaccination with live or live attenuated vaccines is required, these vaccines should be administered at least 4 weeks before treatment and at least 2 weeks after the last dose of efgartigimod alfa. However, other vaccines may be administered as needed at any time during treatment with efgartigimod alfa.
PSUSA/11014 /202212	Periodic Safety Update EU Single assessment - efgartigimod alfa	20/07/2023	15/09/2023	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/11014/202212.

IB/0010/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	24/08/2023	n/a		
IB/0009	<p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	24/08/2023	n/a		
IA/0008/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p>	30/06/2023	n/a		
IA/0007/G	<p>This was an application for a group of variations.</p>	30/06/2023	n/a		

	<p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p>				
II/0004/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any</p>	14/04/2023	n/a		

	manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes				
IB/0002/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	22/11/2022	15/09/2023	SmPC and PL	
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/09/2022	15/09/2023	PL	